SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Theodore Roosevelt — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientTheodore Roosevelt
Date of birth1858-10-27
IdentifiersMRN HR-NI012-SYN-TD; SSN (made up) 000-12-6157
Document date1882-04-06
AuthorAmos Kettering, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week asthma review after starting maintenance-and-reliever therapy. [S]

History of Present Illness

Mr. Roosevelt returns four weeks after changing from albuterol alone to budesonide-formoterol two inhalations twice daily plus one as needed. He is much better: daytime symptoms on two or three days a week instead of most days, night waking once in four weeks, and he finishes his boxing rounds. He has used 4 to 6 as-needed inhalations a week, mostly before training. The dose counter matches about 90 percent of maintenance doses; he missed some evening doses on late session nights. His home peak flow ranges from 560 to 600 L/min. He has had no hoarseness or sore mouth. He still hopes training alone will eventually be enough. He saw the pulmonologist this morning. [S]

ElementDetail
Interval changeSymptoms two or three days a week; night waking once in four weeks
Reliever use4 to 6 as-needed inhalations a week, mostly before training
AdherenceAbout 90 percent of maintenance doses by dose counter; evening doses missed on late nights
Home peak flow560 to 600 L/min
Medication toleranceNo hoarseness, sore mouth, or tremor
Patient concernWould prefer to rely on exercise rather than medicine

Review of Systems

SystemResultFinding
RespiratoryPositiveMild wheeze on two or three days a week; no cough at night in the last three weeks
Ears, nose, mouth, and throatNegativeNo nasal blockage, sneezing, hoarseness, or sore mouth
GastrointestinalNegativeNo heartburn or reflux
PsychiatricNegativeMood good; sleeping better

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two inhalations as needed for wheeze (bought after an urgent care visit; used most days before intake)Two inhalations every 4 hours as neededRespiratory tract route1881-12-15 to 1882-03-09stoppedS
Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenanceTwo inhalations twice daily, with a spacer, rinsing the mouth afterwardsRespiratory tract route1882-03-09activeS
Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in totalOne inhalation as needed, repeated after a few minutes if needed; maximum 12 inhalations a day including maintenance dosesRespiratory tract route1882-03-09activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1882-04-06Body height175cmS
1882-04-06Body weight72.4kgS
1882-04-06Body mass index (BMI) [Ratio]23.6kg/m2S
1882-04-06Systolic blood pressure116mm[Hg]S
1882-04-06Diastolic blood pressure70mm[Hg]S
1882-04-06Heart rate76/minS
1882-04-06Respiratory rate16/minS
1882-04-06Body temperature36.7CelS
1882-04-06Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1882-04-06Total score [ACT]18{score}S
1882-04-06Fractional concentration of exhaled nitric oxide46[ppb]<=25 [ppb]HighS
1882-04-06Eosinophils [#/volume] in Blood by Automated count0.4210*3/uL0-0.5 10*3/uLNormalS
1882-04-06IgE [Units/volume] in Serum or Plasma260[IU]/mL<=100 [IU]/mLHighS
1882-04-06European house dust mite IgE Ab [Units/volume] in Serum8.4k[IU]/L<=0.35 k[IU]/LHighS

Physical Exam

Vital signs recorded on 1882-04-06; see the Vital Signs section. [S]

SystemFinding
GeneralWell, talking easily
NoseNormal mucosa; no polyps
MouthNo thrush
LungsA few end-expiratory wheezes on forced expiration only
Inhaler techniqueWith his own inhaler and spacer: did not breathe out before the dose and held his breath for only two seconds; corrected, and demonstrated back correctly

Problems

ProblemClinical statusVerificationCodeProvenance
Moderate persistent asthma, uncontrolled at intake, with reversible airflow obstruction on spirometry; synthetic modern diagnosis linked to his documented lifelong asthmaactiveconfirmed J45.40S — Synthetic modern classification confirmed by spirometry; the historical asthma is D and its persistence into adulthood is R.
Myopia, both eyes, corrected with glasses since boyhoodactiveconfirmed H52.13S — Synthetic modern entry linked to his documented near-sightedness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyAsthma Control TestEvery visitCompleted today18, up from 13; not yet at the target of 20
ExaminationInhaler technique with his own deviceEvery visitCompleted todayTwo critical errors corrected; correct on repeat demonstration
Medication safetyAdherence and reliever useEvery visitCompleted todayAbout 90 percent adherence; 4 to 6 as-needed inhalations a week
SurveyExacerbation historyEvery visitCompleted todayNone since starting controller therapy
Self-managementTrigger and exposure review, smoking and vaping statusEvery visit; detailed at diagnosis and yearlyCompleted todayColds and dust are his triggers; never smoker; no vaping; no occupational exposure
Self-managementWritten asthma action planEvery visit and after every exacerbationCompleted todayReviewed; peak-flow zones will be reset once his personal best is confirmed
LaboratoryFeNO, blood eosinophils, total IgE, and specific IgEAs indicated: diagnostic uncertainty, phenotyping, allergen-directed treatmentCompleted todayOrdered by pulmonology: FeNO 46 ppb, eosinophils 0.42 x10³/µL, total IgE 260 IU/mL, dust mite IgE 8.4 kU/L
ReferralPulmonology consultationAt diagnosis of uncontrolled persistent asthmaCompleted todaySeen today; diagnosis confirmed and type 2 phenotype identified
ExaminationSpirometryAt diagnosis, 3 to 6 months after stabilization, then every 1 to 2 yearsDueBaseline at intake; repeat at the three-month review
ExaminationHome peak flow monitoringDaily or with symptoms for moderate to severe asthmaCompleted todayReadings 560 to 600 L/min; personal best still being established
SurveyStep-up or step-down assessmentEvery visitCompleted todayStay at Step 4; correct technique and adherence before any change
ExaminationComorbidity surveillance: rhinitis and sinus disease, reflux, obesity, sleep apnea, vocal cord dysfunction, anxiety and depressionAt diagnosis and yearlyCompleted todayNone found; BMI 23.6; PHQ-2 0 at intake; no stridor or sudden throat tightness to suggest vocal cord dysfunction
Medication safetyVaccination statusYearlyCompleted todayPCV20 given today; influenza vaccine this past autumn
ImagingChest radiograph or CTOnly for atypical features or suspected complicationNot indicatedTypical asthma with reversible obstruction

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026)

Follow-up: Asthma review with spirometry in two months, three months after starting controller therapy. Next scheduled visit 1882-06-08: three-month asthma review with repeat spirometry. [S]